Free Trial
→ The tiny chipmaker set to supply Musk 5 billion chips (From Brownstone Research) (Ad)tc pixel
NASDAQ:PULM

Pulmatrix Q3 2025 Earnings Report

Pulmatrix logo
$1.38 -0.04 (-2.82%)
Closing price 06/9/2026 03:59 PM Eastern
Extended Trading
$1.36 -0.02 (-1.52%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pulmatrix EPS Results

Actual EPS
-$0.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q3 2025
Date
10/16/2025
Time
Before Market Opens
Conference Call Date
Thursday, October 16, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Pulmatrix's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pulmatrix Earnings Headlines

Pulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68509287-pulmatrix-inc-pulmatrix-announces-first-quarter-2026-financial-results-008.htm
Pulmatrix Inc : PULM
May 15, 2026  |  247wallst.comhttps://247wallst.com/companies/pulm/
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
 |  Behind the Markets (Ad)
Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2026-financial-results-302773027.html
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
April 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger-302748188.html
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260413345444/en/pulm-stock-alert-halper-sadeh-llc-is-investigating-whether-pulmatrix-inc.-is-obtaining-a-fair-price-for-its-shareholders/
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA). Another key candidate, PLX100, is being investigated for pulmonary sarcoidosis, a chronic inflammatory disease of the lungs. Both programs have progressed through preclinical and early clinical stages, demonstrating favorable tolerability profiles and the potential to reduce systemic side effects.

Founded in 2005 and headquartered in Lexington, Massachusetts, Pulmatrix combines formulation science with pulmonary pharmacology to advance its pipeline. The company collaborates with leading academic institutions and clinical research centers across the United States to conduct studies in diverse patient populations, leveraging its R&D infrastructure to support efficient development pathways.

Pulmatrix’s leadership team brings extensive experience in respiratory drug development and regulatory strategy. Focused on advancing its inhaled therapies through pivotal trials and strategic partnerships, the company aims to expand its portfolio into additional acute and chronic respiratory conditions, ultimately improving patient outcomes and quality of life.

View Pulmatrix Profile
Earnings Tools